.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
McKinsey
Teva
Covington
UBS
Dow
Federal Trade Commission
Citi
Cipla
Johnson and Johnson

Generated: September 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021180

« Back to Dashboard
NDA 021180 describes ORTHO EVRA, which is a drug marketed by Janssen Pharms and is included in one NDA. It is available from one supplier. Additional details are available on the ORTHO EVRA profile page.

The generic ingredient in ORTHO EVRA is ethinyl estradiol; norelgestromin. There are twenty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norelgestromin profile page.

Summary for NDA: 021180

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 021180

Ingredient-typeProgesterone Congeners
Mechanism of ActionEstrogen Receptor Agonists

Suppliers and Packaging for NDA: 021180

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ORTHO EVRA
ethinyl estradiol; norelgestromin
FILM, EXTENDED RELEASE;TRANSDERMAL 021180 NDA Janssen Pharmaceutical, Inc. 50458-192 50458-192-01 7 d in 1 PATCH (50458-192-01)
ORTHO EVRA
ethinyl estradiol; norelgestromin
FILM, EXTENDED RELEASE;TRANSDERMAL 021180 NDA Janssen Pharmaceutical, Inc. 50458-192 50458-192-15 3 PATCH in 1 CARTON (50458-192-15) > 7 d in 1 PATCH

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength0.035MG/24HR;0.15MG/24HR **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Nov 20, 2001TE:RLD:Yes

Expired Orange Book Patents for NDA: 021180

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms
ORTHO EVRA
ethinyl estradiol; norelgestromin
FILM, EXTENDED RELEASE;TRANSDERMAL021180-001Nov 20, 2001► Subscribe► Subscribe
Janssen Pharms
ORTHO EVRA
ethinyl estradiol; norelgestromin
FILM, EXTENDED RELEASE;TRANSDERMAL021180-001Nov 20, 2001► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Accenture
Argus Health
Chinese Patent Office
US Department of Justice
Mallinckrodt
Cerilliant
Fish and Richardson
QuintilesIMS
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot